Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma

Detalles Bibliográficos
Autores principales: Kurokawa, Masayuki, Naito, Sei, Kato, Tomoyuki, Ushijima, Masaki, Yamagishi, Atsushi, Sakurai, Toshihiko, Nishida, Hayato, Tsuchiya, Norihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875143/
https://www.ncbi.nlm.nih.gov/pubmed/36721690
http://dx.doi.org/10.1016/j.ajur.2022.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875143/
https://www.ncbi.nlm.nih.gov/pubmed/36721690
http://dx.doi.org/10.1016/j.ajur.2022.01.005

Ejemplares similares